Terms: = Endocrine gland cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1
500 results:
1. Discriminating Interpatient Variabilities of RAS Gene Variants for Precision Detection of Thyroid cancer.
Fu G; Chazen RS; MacMillan C; Witterick IJ
JAMA Netw Open; 2024 May; 7(5):e2411919. PubMed ID: 38758552
[TBL] [Abstract] [Full Text] [Related]
2. Evolution of Testicular Germ Cell Tumors in the Molecular Era With Histogenetic Implications.
Kilic I; Acosta AM; Idrees MT
Adv Anat Pathol; 2024 May; 31(3):206-214. PubMed ID: 38525515
[TBL] [Abstract] [Full Text] [Related]
3.
Sfreddo HJ; Koh ES; Zhao K; Swartzwelder CE; Untch BR; Marti JL; Roman BR; Dublin J; Wang RS; Xia R; Cohen JM; Xu B; Ghossein R; Givi B; Boyle JO; Tuttle RM; Fagin JA; Wong RJ; Morris LGT
Thyroid; 2024 Apr; 34(4):450-459. PubMed ID: 38407967
[No Abstract] [Full Text] [Related]
4. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
Yang SP; Nga ME; Bundele MM; Chiosea SI; Tan SH; Lum JHY; Parameswaran R; Lim MY; Li H; Cheah WK; Sek KS; Tan ATH; Loh TKS; Ngiam KY; Tan WB; Huang X; Ho TWT; Lim KH; Lim CM; Singaporewalla RM; Rao AD; Rao NCL; Chua DYK; Chin DC; Wald AI; LiVolsi VA; Nikiforov YE; Tai ES
Cancer Cytopathol; 2024 May; 132(5):309-319. PubMed ID: 38319805
[TBL] [Abstract] [Full Text] [Related]
5. K-Ras(V12) differentially affects the three Akt isoforms in lung and pancreatic carcinoma cells and upregulates E-cadherin and NCAM via Akt3.
Geißert R; Lammert A; Wirth S; Hönig R; Lohfink D; Unger M; Pek D; Schlüter K; Scheftschik T; Smit DJ; Jücker M; Menke A; Giehl K
Cell Commun Signal; 2024 Jan; 22(1):85. PubMed ID: 38291468
[TBL] [Abstract] [Full Text] [Related]
6. Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
[TBL] [Abstract] [Full Text] [Related]
7. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
8. Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.
Lee M; Morris LG
Oncotarget; 2024 Jan; 15():36-48. PubMed ID: 38275291
[TBL] [Abstract] [Full Text] [Related]
9. Molecular Genetics Augment Cytopathologic Evaluation and Surgical Planning of Pediatric Thyroid Nodules.
Spaulding SL; Maayah M; Dinauer CA; Prasad M; Darbinyan A; Morotti R; Christison-Lagay ER
J Pediatr Surg; 2024 May; 59(5):975-980. PubMed ID: 38246817
[TBL] [Abstract] [Full Text] [Related]
10. TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary Thyroid Carcinoma in a Colombian Cohort.
Cruz-Romero SD; González S; Juez JY; Becerra DS; Baldión AM; Hakim JA; González-Devia D; Perdomo S; Rodríguez-Urrego PA
Adv Ther; 2024 Feb; 41(2):792-805. PubMed ID: 38170436
[TBL] [Abstract] [Full Text] [Related]
11. A mutation panel comprising BRAF
Eng ZH; Ahmad Jefry MM; Ng KL; Abdul Aziz A; Mat Junit S
Malays J Pathol; 2023 Dec; 45(3):375-390. PubMed ID: 38155379
[TBL] [Abstract] [Full Text] [Related]
12. Genomic profiling of primary and metastatic thyroid cancers.
Máximo V; Melo M; Zhu Y; Gazzo A; Sobrinho Simões M; Da Cruz Paula A; Soares P
Endocr Relat Cancer; 2024 Feb; 31(2):. PubMed ID: 38015791
[TBL] [Abstract] [Full Text] [Related]
13. Mucinous cystadenocarcinoma of the breast harbours TRPS1 expressions and PIK3CA alterations.
Chen WY; Hu YH; Tsai YH; Hang JF; Tan PH; Chen CJ
Histopathology; 2024 Feb; 84(3):550-555. PubMed ID: 37983855
[TBL] [Abstract] [Full Text] [Related]
14. Fine-needle biopsy of thyroid nodules and the contribution of molecular analysis of BRAF and RAS mutations.
Kasko M; Grigerova M; Alemayehu A; Zavodna K; Kasko V; Podoba J
Bratisl Lek Listy; 2023; 124(12):869-872. PubMed ID: 37983279
[TBL] [Abstract] [Full Text] [Related]
15. Macrofollicular Architecture in Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Pitfall in Thyroid Practice.
Yadav S; Kandasamy D; Damle N; Goel R; Chumber S; Sharma MC; Boruah M; Agarwal S
Head Neck Pathol; 2023 Dec; 17(4):899-909. PubMed ID: 37775618
[TBL] [Abstract] [Full Text] [Related]
16. Performance of multigene testing in cytologically indeterminate thyroid nodules and molecular risk stratification.
Zhou Y; Wu X; Zhang Y; Li Z; Ge X; Chen H; Mao Y; Ding W
PeerJ; 2023; 11():e16054. PubMed ID: 37744220
[TBL] [Abstract] [Full Text] [Related]
17. A Novel pyroptosis-related signature for predicting prognosis and evaluating tumor immune microenvironment in ovarian cancer.
Yang J; Wang C; Zhang Y; Cheng S; Xu Y; Wang Y
J Ovarian Res; 2023 Sep; 16(1):196. PubMed ID: 37730669
[TBL] [Abstract] [Full Text] [Related]
18. The histologic outcomes of indeterminate thyroid nodules with rat sarcoma mutations: A case series.
Jones M; Abendano DG; Turner M; Sullivan C; Reyes MCD
Diagn Cytopathol; 2023 Dec; 51(12):E332-E337. PubMed ID: 37583345
[TBL] [Abstract] [Full Text] [Related]
19. [Analysis of BRAF and nras mutations in thyroid tumors in patients from Argentina].
Repetto EM; Fernandez L; Lambertini R; Del Valle Jaen A; Ruda Vega V; Moldes S; Lutfi R; Aranda C; Faure E; Oneto A
Medicina (B Aires); 2023; 83(4):505-513. PubMed ID: 37582124
[TBL] [Abstract] [Full Text] [Related]
20. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.
Akkapeddi P; Hattori T; Khan I; Glasser E; Koide A; Ketavarapu G; Whaby M; Zuberi M; Teng KW; Lefler J; Maso L; Bang I; Ostrowski MC; O'Bryan JP; Koide S
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302485120. PubMed ID: 37399416
[TBL] [Abstract] [Full Text] [Related]
[Next]
